Understanding how SHP2 and PLCγ1 affect calcium signaling in pancreatic cancer
Official title: Investigating the role of SHP2-PLCG1 interaction in PDAC calcium signaling and metabolism
Funded at University of Kansas Medical Center · NIH-10912502 · Data updated 2026-11-12
This study is looking at how two proteins, SHP2 and PLCγ1, work together and affect calcium signaling in pancreatic cancer, with the hope of finding new ways to treat this tough disease and help patients live better lives.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $36,764 |
| NIH project number | 5F31CA281118-02 |
| Project ID | NIH-10912502 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with KRAS mutations.
✕Less likely to help
Patients with other types of cancer or those without pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research investigates the interaction between SHP2 and PLCγ1 and its impact on calcium signaling in pancreatic ductal adenocarcinoma (PDAC). By exploring how these proteins influence tumor progression and metabolism, the study aims to uncover new therapeutic targets for this aggressive cancer. Patients may benefit from insights that could lead to innovative treatments that disrupt the cancer's growth mechanisms. The research employs advanced cellular and molecular techniques to analyze the effects of manipulating these interactions in PDAC cells.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with pancreatic cancer.
How similar studies have gone: While the specific interaction of SHP2 and PLCγ1 in PDAC is a novel approach, similar studies targeting upstream regulators of cancer signaling pathways have shown promise in other cancers.
Where this research is happening
-
University of Kansas Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Walsh, Richard Mckinnon — University of Kansas Medical Center
- Study coordinator: Walsh, Richard Mckinnon
Related research
Other NIH-funded projects on the same topics.
-
Targeting epigenomic regulators to assault pancreatic cancer replication stress
This research tests a new way to treat pancreatic cancer by blocking key epigenetic regulators during DNA replication to make cancer cells less able to cope with replication stress.
-
Neoantigen vaccines in pancreatic cancer: overcoming resistance to improve immune responses
This grant supports testing advanced neoantigen vaccines in pancreatic cancer to boost patients' immune responses and potentially improve outcomes.
-
CD11b-activating drug to make pancreatic cancer respond to immunotherapy
A study to see if a CD11b-activating drug (GB1275) can help pancreatic cancer patients respond better to immunotherapy when combined with standard chemotherapy and PD-1 blockers.
-
Targeting autophagy to treat KRAS-mutant pancreatic cancer
This grant explores using approved drugs to block autophagy in KRAS-mutant pancreatic cancer to improve treatment outcomes.
-
Reprogramming PDAC stroma by targeting blood clotting in the tumor environment
A cancer research grant aimed at turning the tough, fibrous pancreatic cancer environment into one that helps treatments work better and supports the body’s immune response.
-
Understanding paracrine signals in pancreatic cancer to improve drug delivery
A patient-focused look at how the tumor’s signaling networks affect treatment delivery in pancreatic cancer and how targeting these networks could help therapies reach tumors more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.